Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tarceva Shows Overall Survival In Phase III Study
OSI and Genentech has reported that Saturn, a pivotal phase III study of Tarceva (erlotinib), showed positive results. It showed an overall survival in patients with advanced non-small
OSI and Genentech has reported that Saturn, a pivotal phase III study of Tarceva (erlotinib), showed positive results. It showed an overall survival in patients with advanced non-small
SOCMA has commended the US Senate for approving legislation that would extend existing chemical security standards for one more year. Reportedly, the Senate voted 84-6 on July 9
Sirius has signed a collaborative agreement with the Assistance Publique -Hopitaux de Paris (AP-HP), to study genomic co-rrelations in severe sepsis patients. The agreement focuses on the continued
Abraxis has completed patient enrollment of a pivotal, phase III clinical study. The study compares the Abraxane for injectable suspension with Taxol (paclitaxel) injection, both in combination with
Oculus Innovative Sciences (OCLS) has entered into an agreement with OroScience. As per the agreement, OroScience was granted exclusive rights to market Microcyn-based oral products in the US,
iGuard.org has announced an agreement with Microsoft HealthVault for a web-based consumer health technology platform. It is expected to help patients and caregivers access timely and reliable information
BioMarin has completed patient enrollment for the phase I/II clinical trial of BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS). The BMN-110 trial is intended for the treatment of the lysosomal
Medarex has intitiated phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease. In this regard, Medarex will receive a milestone payment
Synexus has recruited the highest number of patients for a major global study. The company has recruited 1,221 patients at seven UK sites, averaging 174 patients per site,
AxoGen is all set to start full distribution of Avance Nerve Graft, human tissue product. It is intended to use in the reconstruction of damaged peripheral nerves for